Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides

被引:71
|
作者
Benimetskaya, L
Takle, GB
Vilenchik, M
Lebedeva, I
Miller, P
Stein, CA
机构
[1] Columbia Univ, Dept Med, New York, NY 10032 USA
[2] Columbia Univ, Dept Pharmacol, New York, NY 10032 USA
[3] Innovir Labs, New York, NY 10021 USA
[4] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA
关键词
D O I
10.1093/nar/26.23.5310
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cationic porphyrins form stable complexes with oligo-deoxynucleotides. To evaluate delivery, we used a 20mer phosphorothioate oligomer (Isis 3521) targeted to the 3'-untranslated region of the PKC-alpha mRNA, and complexed it with porphyrin. The expression of PKC-alpha protein and mRNA in T24 bladder carcinoma cells was reduced by similar to 80 +/- 10% at a concentration of oligomer of 3 mu M, and 9 mu M porphyrin. The expression of PKC-beta 1, -delta and -epsilon isoforms was unaffected by this treatment, but elimination of PKC-zeta protein and mRNA were observed, However, treatment with the porphyrin complex of Isis 3522, an oligomer which is directed at the 5' coding region of the PKG-alpha mRNA, was equally effective as Isis 3521 with respect to PKC-alpha, but did not affect PKC-S protein or mRNA levels. Since Isis 3521 has an 11-base region of complementarity with the PKC-zeta mRNA, wheras Isis 3522 has only a 4-base region, the effect of Isis 3521 on PKC-zeta protein and mRNA expression may be due to irrelevant cleavage. Depending upon the desired application, this new strategy may offer several advantages over other methods of antisense oligodeoxynucleotide delivery including efficiency, stability, solubility, relatively low toxicity and serum compatibility. Porphyrins may thus be a potentially useful delivery vehicle for antisense therapeutics and/or target validation.
引用
收藏
页码:5310 / 5317
页数:8
相关论文
共 50 条
  • [21] Targeted delivery of antisense oligodeoxynucleotides to folate receptor-overexpressing tumor cells
    Yang, LJ
    Li, J
    Zhou, W
    Yuan, X
    Li, S
    JOURNAL OF CONTROLLED RELEASE, 2004, 95 (02) : 321 - 331
  • [22] Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides
    André S. Bachmann
    Andrej Surovoy
    Gunter Jung
    K. Moelling
    Journal of Molecular Medicine, 1998, 76 : 126 - 132
  • [23] Interactions of cationic porphyrins with double-stranded oligodeoxynucleotides:: a study by electrospray ionisation mass spectrometry
    Ramos, CIV
    Barros, CM
    Fernandes, AM
    Santana-Marques, MG
    Correia, AJF
    Tomé, JPC
    Carrilho, MDT
    Faustino, MAF
    Tomé, AC
    Neves, MGPMS
    Cavaleiro, JAS
    JOURNAL OF MASS SPECTROMETRY, 2005, 40 (11): : 1439 - 1447
  • [24] Inhibition of Huntingtin by Antisense Oligodeoxynucleotides
    Nellemann, C
    Abell, K
    Hasholt, L
    Norremolle, A
    Sorensen, SA
    EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 : 145 - 145
  • [25] HIV INHIBITION BY ANTISENSE OLIGODEOXYNUCLEOTIDES
    MAG, M
    MUTH, J
    LUCKING, S
    BIESERT, L
    ENGELS, J
    NUCLEOSIDES & NUCLEOTIDES, 1991, 10 (1-3): : 627 - 629
  • [26] Cellular pharmacology of antisense oligodeoxynucleotides
    Schumacher, C
    ANTISENSE TECHNOLOGY, PT B, 2000, 314 : 440 - 454
  • [27] In vitro and in vivo delivery of antisense oligodeoxynucleotides using lipofection:: Application of antisense technique to growth suppression of experimental glioma
    Matsuno, A
    Nagashima, T
    Katayama, H
    Tamura, A
    ANTISENSE TECHNOLOGY, PT A: GENERAL METHODS, METHODS OF DELIVERY, AND RNA STUDIES, 2000, 313 : 359 - 372
  • [28] CELLULAR UPTAKE OF ANTISENSE OLIGODEOXYNUCLEOTIDES
    JAROSZEWSKI, JW
    COHEN, JS
    ADVANCED DRUG DELIVERY REVIEWS, 1991, 6 (03) : 235 - 250
  • [29] ANTISENSE OLIGODEOXYNUCLEOTIDES AS ANTIVIRAL AGENTS
    COHEN, JS
    ANTIVIRAL RESEARCH, 1991, 16 (02) : 121 - 133
  • [30] Delivery of antisense vectors and antisense oligonucleotides by means of the new cationic lipids Unifectin and Maxifectin
    Flechsler, I
    Surovoy, A
    Charisee, K
    Bayer, E
    Jung, G
    CANCER GENE THERAPY, 1997, 4 (05) : 328 - 328